Source: Eur Respir Rev, 29 (155) 190102; 10.1183/16000617.0102-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Michael J. Hughes, Helen M. McGettrick, Elizabeth Sapey. Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2 diabetes: the neutrophil as a potential inflammatory target. Eur Respir Rev, 29 (155) 190102; 10.1183/16000617.0102-2019

Member's Comments

No comment yet.

Related content which might interest you: The evaluation of systemic inflammation in COPD patients comorbided with cardiovascular diseases or diabetes mellitus Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 COPD: inflammatory mechanisms and systemic consequences Source: Eur Respir Mon 2013; 59: 13-27 Year: 2013 The impact of aging on COPD, cardiovascular comorbidities and systemic inflammation Source: International Congress 2019 – Cardiovascular comorbidities in COPD Year: 2019 Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Source: Eur Respir J 2008; 32: 962-969 Year: 2008 Metabolic syndrome and diabetes mellitus in COPD Source: Eur Respir Mon 2013; 59: 117-134 Year: 2013 Approach to the diagnostics of early carbon metabolism disorders and diabetes mellitus 2 type in COPD patients Source: Annual Congress 2013 –COPD diagnosis Year: 2013 COPD, an inflammatory systemic disease. Inflammatory parameters in a group of COPD patients Source: International Congress 2014 – Lung function, COPD and inflammation Year: 2014 Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1 Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Inflammatory markers of atherogenesis in patients with uncontrolled severe asthma Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Is there a strong relationship between COPD and cardiovascular diseases? Source: Annual Congress 2013 –The latest insights in respiratory muscles, neuromuscular disease and comorbidities Year: 2013 Fructosamine-3-Kinase: A molecular link between COPD and diabetes regulating carbonyl stress and the impact of metformin treatment Source: International Congress 2015 – New insights into lung disease pathogenesis Year: 2015 Cardiovascular risk, subclinical atherosclerosis and markers of systemic inflammation in patients with COPD and frequent exacerbator phenotype Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Some pathogenetic mechanisms of inflammatory processes in smoking patients with COPD Source: Annual Congress 2007 - Smoking and the lung Year: 2007 The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 ß2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities Source: Eur Respir Monogr 2020; 88: 229-237 Year: 2020 Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 Metabolic regulation during the co-existence of COPD and DM type2 Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Increased oxidative stress in patients with chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MetS) Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013